This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Moving the Needle in Bipolar I Depression: Novel Strategies to Improve Patient Outcomes

Moving the Needle in Bipolar I Depression: Novel Strategies to Improve Patient Outcomes



Time to Complete

30 minutes


July 26, 2019


July 26, 2020
Add to Queue

Maximum Credits

0.50 / AMA PRA Category 1 CreditsTM
0.50 / AAPA Category 1 CME Credits
0.50 / CE for Nurse Practitioners (0.50 pharmacology credit)

Accredited Provider

This educational initiative is provided by CME Outfitters.

Commercial Supporter

Supported by an educational grant from Allergan.

Program Description

Bipolar I depression is a serious, debilitating disorder, and the challenge of management is compounded by the limited treatment options that are available. Current D2-targeted strategies to manage bipolar depression are limited in their effectiveness, as these approaches do not specifically target the neurobiology of the disease.

Data is emerging that demonstrates that the novel treatment strategies that target D3 receptors have shown significant clinical benefit in reducing symptom burden and improving quality of life in patients with bipolar I depression.

This CME Outfitters Snack features a faculty-guided interactive 3-D model animation that examines how D3 receptors relate to the pathogenesis of the bipolar I depression, and subsequently, how D3-targeted therapies exert their beneficial effects in promoting symptomatic remission and functional recovery.

Intended Audience

Psychiatrists, primary care physicians, physician assistants, and nurse practitioners who treat patients with bipolar I depression.

Educational Objectives

At the end of this CME/CE activity, participants should be able to:

  • Evaluate the role of dopamine D3 receptor function in the pathogenesis of bipolar I depression.
  • Analyze the current standards of care for bipolar I depression and their limitations in achieving ideal outcomes.
  • Incorporate recent clinical trial data on novel therapies with unique MOAs to achieve optimal clinical outcomes in bipolar I depression.

Conflict Of Interest Disclosure Policy

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.


Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology
University of Toronto
Chairman and Executive Director, Brain and Cognition Discovery Foundation (BCDF)
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, Canada
Director, Depression and Bipolar Support Alliance (DBSA)
Chicago, IL
Professor and Nanshan Scholar, Guangzhou Medical University
Guangzhou, China
Adjunct Professor College of Medicine, Korea University
Seoul, Republic of Korea

Dr. McIntyre reports that he receives grants from CIHR/GACD/Chinese National Natural Research Foundation; and Stanley Medical Research Institute. He receives research support from CIHR/GACD/Chinese National Research Foundation; and Stanley Medical Research Institute. He is on the speakers bureau for Allergan; Janssen Pharmaceutical, Inc.; Lundbeck Canada Inc.; Minerva Neurosciences; Neurocrine Biosciences, Inc.; Otsuka Canada Pharmaceutical Inc.; Pfizer Inc.; Purdue Pharma Canada; Shire Pharma Canada ULC; Sunovion Pharmaceuticals Canada Inc.; and Takeda Pharmaceutical Company Limited.

Christoph U. Correll, MD
Professor of Psychiatry and Molecular Medicine
Hofstra Northwell School of Medicine
Hempstead, NY
Investigator, Center for Psychiatric Neuroscience
Feinstein Institute for Medical Research
Manhasset, NY
Medical Director, Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital, Department of Psychiatry
Glen Oaks, NY

Dr. Correll reports that he receives grants and research support from Janssen Pharmaceutical, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Alkermes; Allergan; Angelini Pharma Inc.; Boehringer-Ingelheim; Gedeon Richter; Gerson Lehrman Group, Inc.; Indivior; IntraCellular Therapies; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; LB Pharmaceuticals; Lundbeck; MedAvante-ProPhase, Inc.; Neurocrine Biosciences, Inc.; Novel Pharmaceuticals, Inc.; Pfizer Inc.; Recordati; Rovi; Servier; Sumitomo Dainippon Pharma Co., Ltd.; Sunovian Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceutical Industries Ltd. He is a stock shareholder (directly purchased) of Janssen Pharmaceutical, Inc.; and Otsuka America Pharmaceutical, Inc. He provides expert testimony for Bristol-Myers Squibb Company. He is a Data Safety Monitoring Board Member/Chair for Boehringer-Ingelheim; Lundbeck; Rovi; Supernus Pharmaceuticals, Inc.; and Teva Pharmaceutical Industries Ltd.

Accredited Provider Disclosure

The CME Outfitters, LLC staff has nothing to disclose.

Planners' and Managers' Disclosures

Tony Graham, MD, (peer reviewer) has no disclosures to report.
Ms. Ochoa (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD, (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.




AAPA Category I CME credit

Accreditation Statement

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria.

Designation Statement

This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid for one year from 05/24/19. PAs should only claim credit commensurate with the extent of their participation.




CE for Nurse Practitioners

Accreditation Statement

This activity was planned in accordance with AANP Accreditation Standards and Policies.

Designation Statement

This activity is approved for 0.50 contact hour(s) of continuing education (which includes 0.50 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19043698.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure of Unlabeled Use

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


There are no fees for participating in this CME/CE activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.

To obtain a certificate, participants must receive a score of 75% or better on the post-test. The post-test can be accessed at the end of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact CME Outfitters at 877-263-7767.

If you have any other questions relating to your certificate or other issues with this activity, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue